WallStSmart

AbbVie Inc (ABBV)vsThe Joint Corp (JYNT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 112648% more annual revenue ($66.01B vs $58.55M). ABBV leads profitability with a 15.7% profit margin vs 6.5%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

JYNT

Hold

49

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 6/9Altman Z: 0.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-87.6%)

Margin of Safety

-87.6%

Fair Value

$157.25

Current Price

$294.64

$137.39 premium

UndervaluedFair: $157.25Overvalued

Intrinsic value data unavailable for JYNT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

JYNT3 strengths · Avg: 9.3/10
EPS GrowthGrowth
653.0%10/10

Earnings expanding 653.0% YoY

Return on EquityProfitability
20.9%9/10

Every $100 of equity generates 21 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

JYNT4 concerns · Avg: 2.8/10
Market CapQuality
$106.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.5%3/10

6.5% margin — thin

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

PEG RatioValuation
8.832/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : JYNT

The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : JYNT

The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 53.6x leaves little room for execution misses.

Key Dynamics to Monitor

ABBV profiles as a mature stock while JYNT is a value play — different risk/reward profiles.

JYNT carries more volatility with a beta of 1.16 — expect wider price swings.

JYNT is growing revenue faster at 14.4% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 49/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

The Joint Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Joint Corp. The company is headquartered in Scottsdale, Arizona.

Visit Website →

Want to dig deeper into these stocks?